Efficacy and Safety of Efgartigimod for Patients With Guillain–Barré Syndrome: A Retrospective Cohort Study (P7-9.015)

Yongli Tao; Ting Yang; Rui Zhang

doi:10.1212/wnl.0000000000216027

June 9, 2026Neurology

Efficacy and Safety of Efgartigimod for Patients With Guillain–Barré Syndrome: A Retrospective Cohort Study (P7-9.015)

View at Publisher

Ask AI

Bookmark

Share

Key Points

Evaluate the efficacy and safety of efgartigimod in patients with Guillain–Barré Syndrome compared to IVIg.
Retrospective cohort study design
Comparative analysis of efgartigimod, IVIg, and IVIg plus efgartigimod
Evaluation of safety and efficacy outcomes
Efgartigimod demonstrated improved efficacy compared to IVIg alone.
Safety profile of efgartigimod was acceptable compared to traditional treatments.

Implication

Retrospective cohort study evaluates efgartigimod's efficacy and safety in Guillain–Barré Syndrome, suggesting potential benefits.

Abstract

This study was to evaluate the efficacy and safety of efgartigimod compared to intravenous immunoglobulin G (IVIg) and IVIG plus efgartigimod for GBS patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tao et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf32afaef96ed7f0559d4 https://doi.org/10.1212/wnl.0000000000216027

View at Publisher

Ask AI

Bookmark

Share

Efficacy and Safety of Efgartigimod for Patients With Guillain–Barré Syndrome: A Retrospective Cohort Study (P7-9.015)

Key Points

Implication

Abstract

Discussion

Cite This Study

Efficacy and Safety of Efgartigimod for Patients With Guillain–Barré Syndrome: A Retrospective Cohort Study (P7-9.015)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology